Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.

Authors
  • Suzuki, Kazuhito
  • Terui, Yasuhito
  • Nishimura, Noriko
  • Ueda, Kyoko
  • Mishima, Yuko
  • Sakajiri, Sakura
  • Yokoyama, Masahiro
  • Aiba, Keisuke
  • Hatake, Kiyohiko
Type
Published Article
Journal
Japanese Journal of Clinical Oncology
Publisher
Oxford University Press
Publication Date
May 01, 2014
Volume
44
Issue
5
Pages
435–441
Identifiers
DOI: 10.1093/jjco/hyu017
PMID: 24664944
Source
Medline
Keywords
License
Unknown

Abstract

The rapid anemia progression index is related to clinical tumor-lysis syndrome associated with bortezomib treatment for multiple myeloma patients with a cut-off point of -1.12 g/dl/month.

Report this publication

Statistics

Seen <100 times